Home

CLICK HERE
to read more customer reviews

"We perform gene editing in primary human immune cells for basic research, drug discovery, and to develop new cell therapies. Cergentis has helped us characterize the on- and off-target integrations when non-virally targeting new genetic material into human T cells with CRISPR, aiding our push towards clinical translation."

"TLA outperforms traditional methods used in CHO cell line characterisation and provides higher resolution and sensitivity.”